Healthcare / Drug Manufacturers - GeneralBSE
$238.45
-7.70 (-3.13%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $337.4M · quality 57.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
64/100
B
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$108.1B
P/E
30.7x
↑EV/EBITDA
15.4x
↑ROE
13.8%
↑Gross Margin
56.7%
↑Debt/Equity
0.11
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+16.8%
FCF CAGR
+21.2%
FCF margin
11.1%
FCF / Net income
0.78x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $29.51B · net income $4.18B · FCF $3.28B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $29.51B | $29.51B | $26.23B | $21.74B | $18.50B |
| Net Income | $4.18B | $4.18B | $3.81B | $3.14B | $2.66B |
| EBITDA | $6.83B | $6.83B | $5.99B | $5.09B | $3.95B |
| EPS | 9.22 | 9.22 | 8.40 | 6.92 | 6.41 |
| Gross Margin | 56.7% | 56.7% | 56.4% | 49.5% | 48.2% |
| Operating Margin | 17.0% | 17.0% | 17.1% | 17.8% | 16.9% |
| Net Margin | 14.2% | 14.2% | 14.5% | 14.4% | 14.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.11 | 0.11 | 0.13 | 0.12 | 0.07 |
| Current Ratio | 5.18 | 5.18 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $3.28B | $3.28B | $337.4M | $215.7M | $1.84B |
| Returns | |||||
| ROE | 13.8% | 13.8% | 15.4% | 15.2% | 15.3% |
| Valuation | |||||
| P/E | 30.73 | 30.73 | 24.61 | 23.26 | 11.27 |
| EV/EBITDA | 15.39 | 15.39 | 15.34 | 14.02 | 6.93 |
| P/B | 3.58 | 3.58 | 3.80 | 3.53 | 1.72 |
| Growth & Yield | |||||
| Revenue Growth | 12.5% | 12.5% | 20.6% | 17.5% | — |
| EPS Growth | 9.8% | 9.8% | 21.4% | 8.0% | — |
| Dividend Yield | 0.4% | 0.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
31.9%
EPS terminal req.
$21.16
Spread vs growth
-22.1%
5Y implied EPS CAGR
22.7%
EPS terminal req.
$25.60
Spread vs growth
-12.9%
10Y implied EPS CAGR
16.2%
EPS terminal req.
$41.23
Spread vs growth
-6.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-2.9%
Start / end P/E
29.4x → 25.9x
EPS bridge
8.40 → 9.22
Residual
-1.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.